ClinicalTrials.gg
CompletedNCT02063360Updated Aug 8, 2017

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

A Phase 1 interventional study of BMS-663068 and Darunavir (DRV) in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-08.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.

Read the detailed description

Brief title: drug-drug interaction (DDI)

Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy subjects

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,094 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 42 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects with no deviation from normal in medical history, physical examination findings, 12-lead measurements, and clinical laboratory tests
  • Women of (WOCBP) allowed. Must be practicing highly effective methods of

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical condition
  • Unable to tolerate oral medications
  • Inability to be venipunctured and/or tolerate venous access
  • Current or recent (within 3 months of dosing) gastrointestinal disease
  • Abnormal liver function test
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cohort 1: BMS-663068+DRV/RTV

    Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16

    Drug: BMS-663068 · Drug: Darunavir (DRV) · Drug: Ritonavir (RTV)

  • Experimental
    Cohort 2: BMS-663068+ETR

    Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16

    Drug: BMS-663068 · Drug: Etravirine (ETR)

  • Experimental
    Cohort 3: BMS-663068+DRV/RTV+ETR

    Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16

    Drug: BMS-663068 · Drug: Darunavir (DRV) · Drug: Ritonavir (RTV) · Drug: Etravirine (ETR)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-626529

    Time frame: 20 timepoints up to day 26

  2. Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529

    Time frame: 20 timepoints up to day 26

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR

    Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)

  2. Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR

    Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)

  3. Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR

    Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)

  4. Cmax for DRV, RTV, and ETR

    Time frame: 24 timepoints up to 26 day

  5. AUC(TAU) for DRV, RTV, and ETR

    Time frame: 24 timepoints up to 26 day

  6. Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs

    Time frame: Up to day 27

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22. PubMed 35315687 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2014
First posted
Feb 14, 2014
Start
Feb 1, 2014
Primary completionActual
May 1, 2014
CompletionActual
May 13, 2014
Last update
Aug 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02063360
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 14, 2014
Start date
Feb 1, 2014
Primary completion
May 1, 2014
Completion
May 13, 2014
Last update
Aug 8, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fostemsavir · Darunavir · Ritonavir · Etravirine

Start the discussion